Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice

Fang Wang, Zhiping Wang, Hongwei Tian, Meijiao Qi, Zhenxing Zhai, Shuwen Li, Renju Li, Hongjuan Zhang, Wenyun Wang, Shenjun Fu, Jianzhong Lu, Ronald Rodriguez, Yinglu Guo, Liqun Zhou

Research output: Contribution to journalArticle

Abstract

Background: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UP II-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. Materials and Method: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. Results: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5×108 pfu or higher dose (5×109 pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5×109 pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. Conclusions: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5×107 pfu and 5×108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalCurrent Gene Therapy
Volume12
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Heterografts
Urinary Bladder Neoplasms
Adenoviridae
Nude Mice
Safety
Neoplasms
Urinary Bladder
Virus Replication
Luciferases
Transgenes
Health Behavior
Transaminases
Western Blotting
Body Weight
Clinical Trials
Gene Expression
Polymerase Chain Reaction
Injections
Liver
Health

Keywords

  • Biodistribution
  • Bladder cancer
  • Gene therapy
  • Oncolytic adenovirus
  • Safety assessment

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)
  • Drug Discovery

Cite this

Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. / Wang, Fang; Wang, Zhiping; Tian, Hongwei; Qi, Meijiao; Zhai, Zhenxing; Li, Shuwen; Li, Renju; Zhang, Hongjuan; Wang, Wenyun; Fu, Shenjun; Lu, Jianzhong; Rodriguez, Ronald; Guo, Yinglu; Zhou, Liqun.

In: Current Gene Therapy, Vol. 12, No. 2, 04.2012, p. 67-76.

Research output: Contribution to journalArticle

Wang, F, Wang, Z, Tian, H, Qi, M, Zhai, Z, Li, S, Li, R, Zhang, H, Wang, W, Fu, S, Lu, J, Rodriguez, R, Guo, Y & Zhou, L 2012, 'Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice', Current Gene Therapy, vol. 12, no. 2, pp. 67-76. https://doi.org/10.2174/156652312800099599
Wang, Fang ; Wang, Zhiping ; Tian, Hongwei ; Qi, Meijiao ; Zhai, Zhenxing ; Li, Shuwen ; Li, Renju ; Zhang, Hongjuan ; Wang, Wenyun ; Fu, Shenjun ; Lu, Jianzhong ; Rodriguez, Ronald ; Guo, Yinglu ; Zhou, Liqun. / Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. In: Current Gene Therapy. 2012 ; Vol. 12, No. 2. pp. 67-76.
@article{0b53d69a0eea4e0eb43d790b46dc8a48,
title = "Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice",
abstract = "Background: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UP II-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. Materials and Method: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. Results: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5×108 pfu or higher dose (5×109 pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5×109 pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. Conclusions: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5×107 pfu and 5×108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior.",
keywords = "Biodistribution, Bladder cancer, Gene therapy, Oncolytic adenovirus, Safety assessment",
author = "Fang Wang and Zhiping Wang and Hongwei Tian and Meijiao Qi and Zhenxing Zhai and Shuwen Li and Renju Li and Hongjuan Zhang and Wenyun Wang and Shenjun Fu and Jianzhong Lu and Ronald Rodriguez and Yinglu Guo and Liqun Zhou",
year = "2012",
month = "4",
doi = "10.2174/156652312800099599",
language = "English (US)",
volume = "12",
pages = "67--76",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice

AU - Wang, Fang

AU - Wang, Zhiping

AU - Tian, Hongwei

AU - Qi, Meijiao

AU - Zhai, Zhenxing

AU - Li, Shuwen

AU - Li, Renju

AU - Zhang, Hongjuan

AU - Wang, Wenyun

AU - Fu, Shenjun

AU - Lu, Jianzhong

AU - Rodriguez, Ronald

AU - Guo, Yinglu

AU - Zhou, Liqun

PY - 2012/4

Y1 - 2012/4

N2 - Background: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UP II-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. Materials and Method: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. Results: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5×108 pfu or higher dose (5×109 pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5×109 pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. Conclusions: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5×107 pfu and 5×108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior.

AB - Background: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UP II-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. Materials and Method: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. Results: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5×108 pfu or higher dose (5×109 pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5×109 pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. Conclusions: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5×107 pfu and 5×108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior.

KW - Biodistribution

KW - Bladder cancer

KW - Gene therapy

KW - Oncolytic adenovirus

KW - Safety assessment

UR - http://www.scopus.com/inward/record.url?scp=84860265783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860265783&partnerID=8YFLogxK

U2 - 10.2174/156652312800099599

DO - 10.2174/156652312800099599

M3 - Article

VL - 12

SP - 67

EP - 76

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 2

ER -